Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5805007 | 0.99 | TLR7 (0.64) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL22043512 | 0.88 | TLR7 (0.62) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL6105045 | 0.86 | TLR7 (0.60) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL22803659 | 0.85 | TLR7 (0.73) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL30773474 | 0.85 | TLR7 (0.73) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL8123283 | 0.85 | TLR7 (0.60) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL13248614 | 0.83 | TLR7 (0.70) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL8121983 | 0.82 | TLR7 (0.56) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL27212290 | 0.82 | TLR7 (0.65) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL3185729 | 0.81 | TLR7 (0.67) | TLR7NUDT1LMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0603251-B1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING & MFG (US) | 2000-10-18 | — | — | EP | claimed |
| EP-0603251-A1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-06-29 | — | — | EP | claimed |
| US-5268376-A | Containing alkoxy substitution | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-12-07 | — | — | US | claimed |
| WO-1993005042-A1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-03-18 | — | — | WO | claimed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | ORBUS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | disclosed |
| CN-117530943-A | Formulations for administration of efluromithine | 奥巴斯治疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-11439612-B2 | Formulations for administration of eflornithine | Orbus Therapeutics, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210038549-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10786470-B2 | Formulations for administration of eflornithine | Orbus Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200138758-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| US-20100310606-A1 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-12-09 | — | — | US | disclosed |
| US-7375180-B2 | Methods and compositions related to IRM compounds and Toll-like receptor 8 | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-0603251-B1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING & MFG (US) | 2000-10-18 | — | — | EP | disclosed |
| US-5525612-A | ANTIVIRAL PHARMACEUTICAL COMPOSITION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5346905-A | Induce interferon biosynthesis; viricides, effective against herpes virus; immunomodulators | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0603251-A1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5268376-A | Containing alkoxy substitution | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-12-07 | — | — | US | disclosed |
| WO-1993005042-A1 | 1-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES; INTERMEDIATE AND PHARMACEUTICAL COMPOSITIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786470-B2 | Formulations for administration of eflornithine | EFNA1, IDH1, ABCC5 | TLR7 2504/4885NUDT1 118/4885LMNA 1255/4885 |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, IDH1, ABCC5 | TLR7 2504/4885NUDT1 118/4885LMNA 1255/4885 |
| US-20200138758-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, IDH1, ABCC5 | TLR7 2504/4885NUDT1 118/4885LMNA 1255/4885 |
| US-20210038549-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, KMT5A, ETV1 | TLR7 2522/4885NUDT1 66/4885LMNA 1278/4885 |
| US-11439612-B2 | Formulations for administration of eflornithine | EFNA1, KMT5A, ETV1 | TLR7 2522/4885NUDT1 66/4885LMNA 1278/4885 |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | TLR7 4726/4885NUDT1 80/4885LMNA 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.